This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N. Engl J Med. 2009;361:1349–58.
Massaro AN, Murthy K, Zaniletti I, Cook N, DiGeronimo R, Dizon MLV, et al. Intercenter cost variation for perinatal-hypoxic ischemic encephalopathy in the era of therapeutic hypothermia. J Pediatr. 2016;173:76–83.e1.
Eunson P. The long-term health, social, and financial burden of hypoxic-ischaemic encephalopathy. Dev Med Child Neurol. 2015;57:48–50.
Yildiz EP, Ekici B, Tatli B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother. 2017;17:449–59.
Peng W, Xing Z, Yang J, Wang Y, Wang W, Huang W. The efficacy of erythropoietin in treating experimental traumatic brain injury: a systematic review of controlled trials in animal models. J Neurosurg. 2014;121:653–64.
Razak A, Hussain A. Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. J Perinat Med. 2019;47:478–89.
Yao X, Wang D, Li H, Shen H, Shu Z, Chen G. Erythropoietin treatment in patients with acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials. Curr Drug Deliv. 2017;14:853–60.
Pauliah SS, Shankaran S, Wade A, Cady EB, Thayyil S. Therapeutic hypothermia for neonatal encephalopathy in low- and middle-income countries: a systematic review and meta-analysis. Plos One. 2013; https://doi.org/10.1371/journal.pone.0058834.
Thayyil S, Pant S, Montaldo P, Shukla D, Oliveira V, Ivain P, et al. Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh. Lancet Glob Health. 2021;9:e1273–85.
Ivain P, Montaldo P, Khan A, Elagovan R, Burgod C, Morales MM, et al. Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis. J Perinatol. 2021;41:2134–40.
Liu TS, Yin ZH, Yang ZH, Wan LN. The effects of monotherapy with erythropoietin in neonatal hypoxic-ischemic encephalopathy on neurobehavioral development: a systematic review and meta-analysis. Eur Rev Med Pharm Sci. 2021;5:2318–26.
Pan J, Wu Y, Liu Y, Cheng R, Chen X, Yang Y. The effect of erythropoietin on neonatal hypoxic-ischemic encephalopathy: an updated meta-analysis of randomized control trials. Front Pediatr. 2023; https://doi.org/10.3389/fped.2022.1074287.
Bolte K, Maier RF. Survey on clinical use and non-use of recombinant human erythropoietin in European neonatal units. J Perinat Med. 2020;48:744–50.
Wang Z, Zhang P, Zhou W, Xia S, Zhou W, Zhou X, et al. Neonatal hypoxic-ischemic encephalopathy diagnosis and treatment: a national survey in China. BMC Pediatr. 2021; https://doi.org/10.1186/s12887-021-02737-6.
Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: intention-to-treat versus per-protocol analysis. Perspect Clin Res. 2016;7:144–6.
Bretthauer M, Loberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N. Engl J Med. 2022;387:1547–56.
Mostazir M, Taylor G, Henley WE, Watkins ER, Taylor RS. Per-protocol analyses produced larger treatment effect sizes than intention to treat: a meta-epidemiological study. J Clin Epidemiol. 2021; https://doi.org/10.1016/j.jclinepi.2021.06.010.
Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ. 2010; https://doi.org/10.1136/bmj.c2697.
Acknowledgements
The Journal Club is a collaboration between the American Academy of Pediatrics – Section of Neonatal Perinatal Medicine and the International Society of Evidence-Based Neonatology (EBNEO.org).
Author information
Authors and Affiliations
Contributions
ALM conducted literature review and primarily drafted the manuscript. JLS and KLB assisted by providing supplementary resources for review, offering edits and design modifications, and revising additional drafts. SC offered edits and oversight to sections discussing statistical analysis. All authors reviewed and agreed upon the final submission.
Corresponding author
Ethics declarations
Competing interests
All authors have denied any direct conflicts of interest in regard to funding or financial gain relevant to this manuscript. Of note, Dr. Benninger was involved in the HEAL consortium and is included among the original authors of the 2022 article that is cited. Additionally, Dr. Slaughter is a principal investigator of the PIVOTAL trial which receives supplementary grant funding from Abbott in addition to grant funding from the National Heart, Lung, and Blood Institute (NHLBI) (UH3 HL161338).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Melemed, A.L., Slaughter, J.L., Benninger, K.L. et al. Is erythropoietin beneficial and safe as an adjunctive therapy to therapeutic hypothermia in newborns with hypoxic ischemic injury?. J Perinatol (2023). https://doi.org/10.1038/s41372-023-01773-7
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41372-023-01773-7